These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18593361)

  • 1. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial.
    Elias EG; Zapas JL; McCarron EC; Beam SL; Hasskamp JH; Culpepper WJ
    Cancer Biother Radiopharm; 2008 Jun; 23(3):285-91. PubMed ID: 18593361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.
    Elias EG; Zapas JL; Beam SL; Brown SD
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):15-8. PubMed ID: 15934495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
    J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.
    Spitler LE; Grossbard ML; Ernstoff MS; Silver G; Jacobs M; Hayes FA; Soong SJ
    J Clin Oncol; 2000 Apr; 18(8):1614-21. PubMed ID: 10764421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
    J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
    Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
    J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis.
    Dillman R; Selvan S; Schiltz P; Peterson C; Allen K; Depriest C; McClay E; Barth N; Sheehy P; de Leon C; Beutel L
    Cancer Biother Radiopharm; 2004 Oct; 19(5):658-65. PubMed ID: 15650459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
    Atzpodien J; Fluck M; Reitz M
    Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
    Hodi FS; Lee S; McDermott DF; Rao UN; Butterfield LH; Tarhini AA; Leming P; Puzanov I; Shin D; Kirkwood JM
    JAMA; 2014 Nov; 312(17):1744-53. PubMed ID: 25369488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
    Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
    J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases.
    Hoeller C; Jansen B; Heere-Ress E; Pustelnik T; Mossbacher U; Schlagbauer-Wadl H; Wolff K; Pehamberger H
    J Invest Dermatol; 2001 Aug; 117(2):371-4. PubMed ID: 11511318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
    Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
    J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
    Jaffee EM; Hruban RH; Biedrzycki B; Laheru D; Schepers K; Sauter PR; Goemann M; Coleman J; Grochow L; Donehower RC; Lillemoe KD; O'Reilly S; Abrams RA; Pardoll DM; Cameron JL; Yeo CJ
    J Clin Oncol; 2001 Jan; 19(1):145-56. PubMed ID: 11134207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
    Schwaab T; Tretter C; Gibson JJ; Cole BF; Schned AR; Harris R; Wallen EM; Fisher JL; Waugh MG; Truman D; Stempkowski LM; Crosby NA; Heaney J; Ernstoff MS
    J Urol; 2004 Mar; 171(3):1036-42. PubMed ID: 14767265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.